SEMA6B and Hepatic failure: To explore the clinical potential of SEMA6B, we administered synthetic SEMA6B siRNA in a mouse model of liver failure, as depicted in Figure 9A. The SEMA6B knockdown in mice was confirmed through qRT-PCR and Western blot analyses (Figure 9B-C).